| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/ECP.11.28 |
| P698 | PubMed publication ID | 22114860 |
| P2093 | author name string | Christina Antoniou | |
| Alexander J Stratigos | |||
| Petros P Sfikakis | |||
| Theognosia Vergou | |||
| Aikaterini-Evangelia Moustou | |||
| P2860 | cites work | The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions | Q37696090 |
| Cytokine modulation of adhesion molecules in the regulation of immunologic cytotoxicity of epidermal targets | Q38010159 | ||
| Functional comparisons of different tumour necrosis factor receptor/IgG fusion proteins | Q38289674 | ||
| Epidermal CD8+ T cells in chronic plaque psoriasis are Tc1 cells producing heterogeneous levels of interferon-gamma | Q40802615 | ||
| A novel p75TNF receptor isoform mediating NFkappa B activation | Q40816200 | ||
| Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions | Q41355139 | ||
| Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept | Q42479845 | ||
| Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs | Q46143952 | ||
| CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. | Q52918582 | ||
| Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. | Q53787487 | ||
| Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists | Q56864876 | ||
| Autoimmune Diseases Induced by TNF-Targeted Therapies | Q56907567 | ||
| The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games | Q24683018 | ||
| Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial | Q28202251 | ||
| The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor | Q28610826 | ||
| Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases | Q29547555 | ||
| Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore | Q30715893 | ||
| Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study | Q33371653 | ||
| A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling | Q33907802 | ||
| Construction and initial characterization of a mouse-human chimeric anti-TNF antibody | Q34060890 | ||
| Keratins (Kl6 and Kl7) as markers of keratinocyte hyperproliferation in psoriasis in vivo and in vitro | Q34296920 | ||
| The immunologic basis for the treatment of psoriasis with new biologic agents | Q34470558 | ||
| The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiat | Q34505900 | ||
| The TNF-TNF receptor system | Q35009296 | ||
| Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis | Q35554321 | ||
| The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor | Q35739690 | ||
| Biology of tumor necrosis factor-alpha- implications for psoriasis | Q35746601 | ||
| Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses | Q36294340 | ||
| Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection | Q36555176 | ||
| Interleukin-12, interleukin-23, and psoriasis: current prospects | Q36913621 | ||
| Tumor necrosis factor antagonist mechanisms of action: a comprehensive review | Q37043901 | ||
| Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review | Q37560336 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacodynamics | Q725307 |
| TNF | Q18032037 | ||
| P304 | page(s) | 515-523 | |
| P577 | publication date | 2011-07-01 | |
| P1433 | published in | Expert Review of Clinical Pharmacology | Q15793519 |
| P1476 | title | Pharmacodynamics of TNF-α inhibitors in psoriasis | |
| P478 | volume | 4 |
Search more.